VCEL Vericel Corporation

Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, will be presenting at the following investor and industry conferences:

• Nick Colangelo, president and CEO, will present at the Ladenburg 2018 Healthcare Conference in New York, NY on Tuesday, October 2, 2018 at 11:30 AM EDT http://wsw.com/webcast/ladenburg4/vcel/
• Nick Colangelo, president and CEO, will present at the Cantor Global Healthcare Conference in New York, NY on Wednesday, October 3, 2018 at 1:40 PM EDT http://wsw.com/webcast/cantor7/vcel/
• Dan Orlando, Chief Operating Officer, will present at the Cell & Gene Meeting on the Mesa in La Jolla, CA on, Thursday, October 4, 2018 at 5:15 PM PDT http://www.meetingonthemesa.com/webcast

About Vericel CorporationVericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at www.vcel.com.

Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights reserved.

Global Media Contacts:David SchullRusso Partners LLC+1 212-845-4271 (office)+1 858-717-2310 (mobile)David.schull@russopartnersllc.com

Karen ChaseRusso Partners LLC+1 646-942-5627 (office)+1 917-547-0434 (mobile)Karen.chase@russopartnersllc.com

Investor Contacts:Chad RubinSolebury Troutcrubin@troutgroup.com+1 (646) 378-2947

Lee SternSolebury Troutlstern@troutgroup.com+1 (646) 378-2922